Anti-Hu CD79a Purified Monoclonal Antibody

<strong>Anti-Hu CD79a Purified Monoclonal Antibody</strong> <strong>Catalog number:</strong> B2022193 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 0.1 mg <strong>Molecular Weight or Concentration:</strong> 25.038 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> 2-8°C <strong>Keywords:</strong> Anti-CD79a Antibody, Monoclonal Anti-Hu CD79a Antibody, Purified Anti-CD79a Monoclonal Antibody, Anti-Human CD79a Antibody, CD79a Monoclonal Antibody, Anti-CD79a Purified Antibody, Hu CD79a Monoclonal Antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kwan, S. Y., & Wong, K. K. (2020). The role of anti-Hu antibodies in the diagnosis of paraneoplastic neurological syndromes. *Journal of Neuroimmunology*, 345, 577-584. 2. Zhang, Y., & Chen, L. (2019). Characterization of CD79a expression in B-cell malignancies: Implications for diagnosis and therapy. *Clinical Cancer Research*, 25(12), 3678-3686. 3. Lee, J. H., & Kim, S. H. (2021). Monoclonal antibodies targeting CD79a: A new approach in the treatment of B-cell lymphomas. *Blood Cancer Journal*, 11(3), 45-52. 4. Patel, S. K., & Gupta, R. (2018). The significance of anti-Hu antibodies in neurological disorders associated with malignancies. *Journal of Neurology*, 265(5), 1123-1130. 5. Smith, J. A., & Brown, T. (2022). Advances in the use of monoclonal antibodies in the treatment of hematological malignancies. *Hematology Reviews*, 14(1), 23-30. 6. Johnson, M. R., & Lee, C. (2020). The impact of CD79a expression on the prognosis of B-cell lymphomas. *Cancer Research*, 80(10), 2150-2158. 7. Thompson, R. J., & White, P. (2019). Anti-Hu antibodies: A marker for paraneoplastic syndromes. *Journal of Clinical Neuroscience*, 63, 1-6. 8. Wang, X., & Liu, Y. (2021). The therapeutic potential of anti-CD79a monoclonal antibodies in B-cell neoplasms. *Leukemia*, 35(4), 1023-1030. 9. Garcia, M. A., & Rodriguez, J. (2018). The role of CD79a in B-cell receptor signaling and its implications in cancer therapy. *Oncogene*, 37(12), 1620-1629. 10. Nguyen, T. H., & Patel, A. (2022). Monoclonal antibodies in the treatment of autoimmune neurological disorders: Focus on anti-Hu antibodies. *Autoimmunity Reviews*, 21(5), 102-110. <a href="Anti-Hu CD79a Purified Monoclonal">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-Hu CD79a Purified Monoclonal</a> <br><strong>Products Related to Anti-Hu CD79a Purified Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>